tender for re-tender for the procurement of anticancer drugs for the year 2026-27 , azathioprine tab ip 50 mg , cyclophosphamide tab ip 50 mg , dacarbazine inj ip/usp 200 mg , dactinomycin inj 0.5 mg/3 ml , daunorubicin inj ip 20 mg , dexamethasone tab ip 8 mg , dexamethasone tab ip 4 mg , enzalutamide cap 80 mg , exemestane tab ip 25 mg , fludarabine phosphate inj ip/ usp 50 mg , ibandronate tab 50 mg , megestrol acetate tab ip/bp/usp 40 mg , melphalan tab ip 5 mg , mercaptopurine tab ip 50 mg , methotrexate inj (intrathecal, preservative free) 15 mg , mitomycin for inj ip/usp 10 mg , mitoxantrone infusion bp/usp 20 mg , procarbazine hcl cap ip 50 mg , rasburicase inj 1.5 mg , regorafenib tab 40 mg , rucaparib tab 300 mg , tegafur +uracil cap 100 mg + 224 mg , vinblastine sulphate inj ip 10 mg , vincristine sulphate inj ip/usp 1 mg , cisplatin inj ip 10 mg , cisplatin inj ip 50 mg , cyclophosphamide inj ip 200 mg , cyclophosphamide inj ip 500 mg , cyclophosphamide inj ip 1 gm , decitabine inj 50 mg , decitabine inj 30 mg , flurouracil inj ip 250 mg , flurouracil inj ip 500 mg , ifosfamide with mesna inj 1 gm , ifosfamide with mesna inj 2 gm , oxaliplatin inj ip 50 mg , oxaliplatin inj ip 100 mg , leucovorin calcium inj ip 15 mg , nilotinib cap 200 mg , nilotinib cap 150 mg